CDO1 and breast cancer: Surprisingly, the combination of serum CDO1 PMR and traditional serum biomarkers 4C had even higher diagnostic efficiency for early BC, with a sensitivity and specificity of 61.54 and 86.11%, respectively, and an AUC of .74 (95% CI: .64−.84).